60 Participants Needed

Dexmedetomidine + Midazolam for Pediatric Delirium

AW
RM
KV
AM
Overseen ByArlene M Williams, RN
Age: < 18
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Massachusetts, Worcester
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

Preventing emergent delirium in pediatric ambulatory surgery through preoperative use of intra-nasal Dexmedetomidine and oral Midazolam.

Research Team

RI

R. Ian Richmond, MD

Principal Investigator

University of Massachusetts Chan Medical School

Eligibility Criteria

This trial is for children aged 3 months to 9 years who are scheduled for ear surgery (myringotomy) and are generally healthy (ASA class I-II). It's not for kids over age 9, those with serious heart defects, or non-English speakers without short form consent.

Inclusion Criteria

Children between 3 months and 9 years old.
You are going to have ear surgery to insert ear tubes.
American Society of Anesthesiologists (ASA) classification of I - II.

Exclusion Criteria

You have a heart condition that has not been fixed, including a type called cyanotic congenital heart disease.
Non-English language speaker for whom short form consent is not available
You have a high risk of medical complications according to your health assessment.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Preoperative

Participants receive either intra-nasal Dexmedetomidine or oral Midazolam before surgery

10-25 minutes
1 visit (in-person)

Surgery and Immediate Postoperative

Surgery is performed and immediate postoperative monitoring occurs, including documentation of end tidal Sevoflurane value and rescue analgesia in PACU

0-6 hours

Follow-up

Participants are monitored for pediatric delirium and oral analgesic use, with home behavior analysis for 48 hours post-operatively

48 hours

Treatment Details

Interventions

  • Dexmedetomidine
  • Midazolam
Trial Overview The study tests if using intra-nasal Dexmedetomidine or oral Midazolam before surgery can prevent confusion and agitation (delirium) in kids after they wake up from anesthesia in outpatient ear surgeries.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Intra-nasal DexmedetomidineExperimental Treatment1 Intervention
Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
Group II: Oral MidazolamActive Control1 Intervention
Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.

Dexmedetomidine is already approved in European Union, United States, Canada, Japan for the following indications:

πŸ‡ͺπŸ‡Ί
Approved in European Union as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
πŸ‡ΊπŸ‡Έ
Approved in United States as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
πŸ‡¨πŸ‡¦
Approved in Canada as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
πŸ‡―πŸ‡΅
Approved in Japan as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Massachusetts, Worcester

Lead Sponsor

Trials
372
Recruited
998,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceΒ·Privacy PolicyΒ·CookiesΒ·Security